Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exelixis, Taconic Farms deal

EXEL sold an 80.1% stake in its Artemis Pharmaceuticals GmbH subsidiary to Taconic for $20

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE